Latest On Madrigal Pharmaceuticals, Inc (MDGL):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-30 02:23 EST | News | Drug pricing watchdog raises alarm over upcoming liver disease meds | N/A |  |
| 2023-05-30 02:23 EST | News | Madrigal: Setting The Pace In The NASH Market (Rating Upgrade) | N/A | |
| 2023-04-18 12:35 EST | News | Madrigal rises on FDA breakthrough therapy tag for liver disease drug resmetirom | N/A | |
| 2023-03-31 07:29 EST | News | Madrigal Pharmaceuticals: Odds Shortening On NASH Drug Approval | N/A | |
| 2023-02-23 17:08 EST | News | Madrigal Pharmaceuticals GAAP EPS of -$4.98 misses by $0.48 | N/A | |
About Madrigal Pharmaceuticals, Inc (MDGL):
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
General
- Name Madrigal Pharmaceuticals, Inc
- Symbol MDGL
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 42
- Last Split Factor1:35
- Last Split Date2016-07-25
- Fiscal Year EndDecember
- IPO Date2007-02-06
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.madrigalpharma.com
Valuation
- Price/Book (Most Recent Quarter) 7.87
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$16.21
- Next Year EPS Estimate -$14.67
- Next Quarter EPS Estimate -$3.80
- Return on Assets -35%
- Return on Equity -62%
- Earnings Per Share -$3.57
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 1.89 billion
- EBITDA -66505000
- Analyst Target Price $170.36
- Book Value Per Share $15.47
Share Statistics
- Shares Outstanding 15.47 million
- Shares Float 7.18 million
- % Held by Insiders 1947%
- % Held by Institutions 93.86%
- Shares Short 2.66 million
- Shares Short Prior Month 2.77 million
- Short Ratio 10.52
- Short % of Float 31%
- Short % of Shares Outstanding 17%
Technicals
- Beta 1.12
- 52 Week High $136.81
- 52 Week Low $56.82
- 50 Day Moving Average 118.41
- 200 Day Moving Average 118.57
Dividends
- Dividend Date 2016-07-25
- ExDividend Date N/A
- Dividend Yield 0%
Madrigal Pharmaceuticals, Inc (MDGL) Dividend Calendar:
MDGL's last dividend payment was made to shareholders on July 25, 2016.
Madrigal Pharmaceuticals, Inc (MDGL) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Madrigal Pharmaceuticals, Inc (MDGL) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Madrigal Pharmaceuticals, Inc (MDGL) Chart:
Madrigal Pharmaceuticals, Inc (MDGL) News:
Below you will find a list of latest news for Madrigal Pharmaceuticals, Inc (MDGL) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Madrigal Pharmaceuticals, Inc (MDGL) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest MDGL Trades:
Madrigal Pharmaceuticals, Inc (MDGL) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-05 | 8-K (Current report) | |
| 2020-11-05 | 8-K (Current report) | |
| 2020-11-05 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-11-05 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-09-08 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-09-04 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-04 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-10 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-06-18 | 8-K (Current report) | |
| 2020-06-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-18 | 4 (Statement of changes in beneficial ownership of securities) | |
Madrigal Pharmaceuticals, Inc (MDGL) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Madrigal Pharmaceuticals, Inc (MDGL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1947%
Institutional Ownership: 9386%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-08-19 | BAY CITY CAPITAL LLC | 10% Share Holder | Sell | 7,303.00 | 107.64 | 786,094.92 | 42,875.00 | |
| 2020-08-19 | FRED B CRAVES | Director | Sell | 7,303.00 | 107.64 | 786,094.92 | 42,875.00 | |
| 2020-08-18 | BAY CITY CAPITAL LLC | 10% Share Holder | Sell | 10,197.00 | 110.03 | 1,121,975.91 | 50,178.00 | |
| 2020-08-18 | FRED B CRAVES | Director | Sell | 10,197.00 | 110.03 | 1,121,975.91 | 50,178.00 | |
| 2020-08-17 | BAY CITY CAPITAL LLC | 10% Share Holder | Sell | 12,500.00 | 110.73 | 1,384,125.00 | 60,375.00 | |
| 2020-08-17 | FRED B CRAVES | Director | Sell | 12,500.00 | 110.73 | 1,384,125.00 | 60,375.00 | |
| 2019-12-13 | BAY CITY CAPITAL LLC | 10% Share Holder | Sell | 1,174,680.00 | 105.47 | 123,893,499.60 | 4,089,702.00 | |
| 2019-12-13 | FRED B CRAVES | Director | Sell | 1,174,680.00 | 105.47 | 123,893,499.60 | 4,089,702.00 | |
| 2019-12-13 | BAY CITY CAPITAL LLC | 10% Share Holder | Sell | 25,320.00 | 105.47 | 2,670,500.40 | 88,152.00 | |
| 2019-12-13 | FRED B CRAVES | Director | Sell | 25,320.00 | 105.47 | 2,670,500.40 | 88,152.00 | |
| 2018-11-21 | DAVID V MILLIGAN | Director | Sell | 20,000.00 | 112.54 | 2,250,800.00 | 0.00 | |
| 2018-11-20 | PAUL A FRIEDMAN | Chief Executive Officer | Buy | 4,000.00 | 117.88 | 471,520.00 | 161,128.00 | |
| 2018-11-19 | PAUL A FRIEDMAN | Chief Executive Officer | Buy | 4,000.00 | 124.00 | 496,000.00 | 157,128.00 | |
| 2018-11-19 | DAVID V MILLIGAN | Director | Sell | 10,000.00 | 131.60 | 1,316,000.00 | 20,000.00 | |
| 2018-11-19 | FRED B CRAVES | Director | Buy | 100.00 | 123.17 | 12,317.00 | 296,167.00 | |
| 2018-11-19 | FRED B CRAVES | Director | Buy | 1,000.00 | 124.57 | 124,570.00 | 297,167.00 | |
| 2018-11-19 | FRED B CRAVES | Director | Buy | 900.00 | 125.00 | 112,500.00 | 298,067.00 | |
| 2018-11-14 | DAVID V MILLIGAN | Director | Buy | 10,000.00 | 16.46 | 164,600.00 | 30,000.00 | |
| 2018-09-18 | DAVID V MILLIGAN | Director | Buy | 20,000.00 | 9.45 | 189,000.00 | 20,000.00 | |
| 2018-06-11 | BAY CITY CAPITAL LLC | Director | Sell | 5,908.00 | 287.46 | 1,698,313.68 | 113,472.00 | |